About this trial
This trial looks at a treatment using a person's own white blood cells. These cells are changed in a lab to attack cancer cells that have special mutations. The goal is to see if this treatment can help shrink tumors in people with certain types of metastatic cancer. Participants will receive the modified cells after a special preparation process.
This is a Phase 2 trial, which means it is looking at how well the treatment works and how safe it is. The trial aims to include about 285 participants. It is regulated by the FDA.
Who can join
Adults aged 18 to 72 years with certain types of metastatic cancer that do not respond to standard treatments can join. Both men and women are eligible. People with specific health conditions, like certain infections or low blood counts, may not be able to participate. The trial team will confirm who can join.
Conditions
Endocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer, Gastrointestinal/Genitourinary Cancers, Neuroendocrine Tumors, Multiple Myeloma
Age group
Adult, Older adult
The study team makes the final call on eligibility.
What happens in the study
Participants will go through a series of steps. They will have tests to prepare for treatment. Some will receive a type of chemotherapy before getting their modified T-cells. There are two study groups: one receives just the modified T-cells, while the other receives those along with another drug called pembrolizumab. Everyone will have follow-up visits to check on their health.
Where
This trial is running at 1 location in the United States. It is currently recruiting.
National Institutes of Health Clinical Center
Bethesda, Maryland